Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 14/20 | 0.39 |
| ▸ | PRMT1 | Q99873 | 12/20 | 0.39 |
| ▸ | PRMT6 | Q96LA8 | 5/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 4/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 3/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17753574 | 0.87 | PTGS2 (0.39) | PTGS2HTR5AMAPK13MAPK12MAPK11 | |
| SCHEMBL16201150 | 0.78 | PRMT1 (0.43) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201160 | 0.74 | PRMT1 (0.36) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201149 | 0.73 | TDP1 (0.47) | MAPK13MAPK12MAPK11MAPK14KDM4E | |
| SCHEMBL16201152 | 0.72 | MAPK14 (0.36) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL23615993 | 0.70 | CARM1 (0.66) | CARM1PRMT1PRMT6PRMT8KDM4E | |
| SCHEMBL16201172 | 0.69 | PRMT6 (0.35) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201157 | 0.69 | MAPT (0.41) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201148 | 0.69 | CARM1 (0.43) | CARM1PRMT1PRMT6PRMT8PRMT3 | |
| SCHEMBL16201203 | 0.68 | PRMT1 (0.34) | CARM1PRMT1PRMT6PRMT8PRMT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9776972-B2 | Pyrazole derivatives as arginine methyltransferase inhibitors and uses thereof | EPIZYME INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2016-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137609-A1 | PYRAZOLE DERIVATIVES AS ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | CARM1 12/4885PRMT1 1/4885PRMT6 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.